Lactate Dehydrogenase to Albumin Ratio as a Predictor of Severe Community-Acquired Pneumonia in Patients Aged 60 years and Above: A Retrospective Cohort Study Authors: Congfeng Li, Mengyu Lian, Lin Ding, Jinxiang Wang Published: 2026 ABSTRACT AbstractPurposeAlthough albumin-based indices have prognostic value in older adults with community-acquired pneumonia (CAP), the predictive role of lactate dehydrogenase to albumin ratio (LAR) remains insufficiently explored. This study aimed to evaluate LAR as a predictor of CAP severity in patients aged ≥60 years.Patients and MethodsWe conducted a retrospective cohort study of patients aged ≥60 years with CAP hospitalized from June 2022 to June 2025 at six secondary and tertiary academic hospitals in China. By stratifying patient into tertiles, we assessed the correlation between LAR and the severity of CAP. To explore the association between LAR and CAP severity, we employed logistic regression analyses, and subgroup analyses based on demographics and comorbidities to validate the robustness of our findings.ResultsA total of 423 patients with CAP were included, of which 102 cases (24.1%) were severe community-acquired pneumonia (SCAP). The average age of the participants was 73.2±7.5 years, with 64.8% being male. Natural logarithm (ln) transformed LAR on admission was significantly linked to the severity of CAP in the unadjusted analysis [Odds Ratio (OR) 23.24; 95% Confidence Interval (CI) 12.09–44.69]. Following controlling for potential variables, the association remained statistically significant (OR 11.41; 95% CI 3.57–36.47). When ln transformed LAR was categorized into tertiles, the severity of CAP in the highest tertile (T3) was significantly higher compared to that in the lowest tertile (T1) (model 4: OR = 9.43, 95% CI: 2.22–39.97). Subgroup analyses supported the stability of these findings.ConclusionLAR may serve as a promising predictor of the severity of CAP and may assist clinicians in identifying high-risk individuals among CAP patients. Future research is warranted to further validate the predictive utility of LAR in different populations and investigate its potential applications in CAP management.Keywords: lactate dehydrogenase to albumin ratio, community-acquired pneumonia, severity Introduction Community-acquired pneumonia (CAP) is a common lower respiratory tract infection, posing a major threat to public health, particularly among older adults who often suffer from weakened immunity and multiple comorbidities, and experience a significantly higher mortality risk of > 29.5% in those aged > 80 years, more than twice that of younger patients (18–40 years).1–5 Severe CAP is characterized by high morbidity, rapid progression, and significant mortality, necessitating accurate risk stratification to guide clinical decision-making and optimize resource utilization.6–9 Traditional inflammatory markers such as C-reactive protein (CRP) and procalcitonin (PCT) may lack sufficient predictive power for CAP severity.10,11 In contrast lactate dehydrogenase (LDH) reflects tissue damage and inflammation, while albumin indicates the inflammatory and nutritional status.12,13 Consequently, albumin-based composite indices have garnered increasing attention. For instance, Eksioglu et al demonstrated that indices such as the Glasgow Prognostic Score and C-reactive protein to albumin ratio may provide additional prognostic information beyond traditional clinical scores like pneumonia severe index (PSI) and CURB-65.14 However, the predictive value of the lactate dehydrogenase to albumin ratio (LAR)-another novel albumin-based inflammatory composite marker-for CAP severity in this specific population remains unclear. While elevated LAR levels have been linked to adverse outcomes in a range of diseases, including cancer, sepsis, acute heart failure, lower respiratory tract infection, COVID-19, and severe fever with thrombocytopenia syndrome,15–21 its role in CAP severity remains unclear. Understanding this relationship could provide clinicians with a valuable tool for risk stratification and management of patients with CAP. This study aims to evaluate the potential of LAR as a predictive biomarker for severe CAP in patients aged ≥ 60 years. By conducting a retrospective cohort study, we hope to provide insights into the utility of this novel marker in clinical practice. Materials and Methods Study Design This retrospective cohort study was conducted at Beijing Luhe Hospital, Capital Medical University. The study was conducted in compliance with the Declaration of Helsinki and received approval from the Ethics Committee of Beijing Luhe Hospital, Capital Medical University (No: 2022-LHKY-040-03). The requirement for individual patient informed consent was waived by the Ethics Committee due to the retrospective and anonymized nature of the data used in this study. Study Population This retrospective cohort study included patients aged 60 years and older, diagnosed with CAP and hospitalized between June 2022 and June 2025. The criteria for CAP diagnosis encompassed symptoms indicative of a lower respiratory tract infection (LRTI). LRTI was defined as: an acute illness (present for 21 days or less), usually with cough as the main symptom, with at least one other lower respiratory tract symptom (sputum production, dyspnea, wheeze or chest discomfort/pain) and no alternative explanation (eg. sinusitis or asthma).22 A diagnosis of CAP was confirmed if the presence of new or progressive infiltrates, consolidations, ground-glass opacities, or interstitial changes on chest radiographs or computed tomography (CT) scans was accompanied by any of the following: symptoms or signs of acute lower respiratory tract infection, or peripheral blood white cell counts exceeding 10×10^9/L or falling below 4×10^9/L.23,24 Exclusion criteria: (1) Patients died within 24 hours; (2) Patients with end - stage disease and an estimated survival time <3 months; (3) Patients diagnosed with hospital-acquired pneumonia; (4) Patients diagnosed without infectious disease; (5) Patients diagnosed pulmonary tuberculosis; (6) Patients without LDH or albumin data within the first 48 hours after hospital admission. The Definition of the Severe Community-Acquired Pneumonia (SCAP) The diagnosis of SCAP was based on the Infectious Diseases Society of America/American Thoracic Society guidelines and required either: necessitating either a single major criterion (septic shock or respiratory failure necessitating mechanical ventilation) or at least three minor criteria, including a respiratory rate ≥30 breaths per minute, a PaO2/FiO2 ratio ≤250, multilobar infiltrates, mental confusion, elevated blood urea nitrogen(BUN) >20 mg/dL, leukopenia <4000/μL, thrombocytopenia <100,000/μL, hypothermia <36°C, or hypotension needing aggressive fluid resuscitation.23 Measurements of LDH/ALB The LAR was determined by calculating the ratio of LDH levels, expressed in units per liter (U/L), to albumin levels, expressed in grams per liter (g/L). Covariates Data extraction was performed manually by medical doctors using the hospital’s electronic medical records system. To ensure the accuracy and reliability of the data, a rigorous double-entry verification process was implemented. No automated search or extraction tools were utilized in this process. Data were collected for each patient upon admission and within 48 hours of laboratory testing. The information gathered included demographic and clinical characteristics such as gender, age, and comorbidities such as hypertension, diabetes mellitus, coronary heart disease, chronic lung disease, chronic renal disease. The severity of illness was assessed by the presence of SCAP at admission. Laboratory results were obtained from routine blood tests, biochemical tests, including albumin (ALB, g/L), alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), glucose (mmol/L), creatine (Crea,umol/L), blood urea nitrogen (BUN, mmol/L), LDH (U/L), C-reactive protein (CRP, mg/L), procalcitonin (PCT, ng/mL), white blood cell (WBC, x109/L), neutrophil (NE, x109/L), hemoglobin (Hb, g/L), lymphocyte (x109/L), arterial blood gas analysis [PH, PCO2 (mmHg), PO2 (mmHg), PaO2/ FIO2 (mmHg)], and PSI score at admission. The PSI classifies patients into five risk classes (I–V) based on demographic characteristics, comorbidities, physical examination findings, and laboratory/radiographic results, with higher classes indicating greater severity and mortality risk.25 Statistical Analysis The study cohort was stratified into three groups based on the tertiles of natural logarithm (ln) transformed LAR to thoroughly analyze the link between LAR levels and CAP severity. Continuous data were described as mean ± standard deviation (SD) if normally distributed or as median [interquartile range (IQR)], while categorical data were presented as relative frequencies (%) and absolute frequencies. For baseline comparisons, continuous variables were compared using the Student’s t-test or the Mann–Whitney U-test based on the normality of the data distribution, while categorical variables were assessed with the chi-square test. We imputed missing values for variables with a rate of less than 10% using the K-Nearest Neighbors (KNN) method.26 A ln transformation was applied to address the skewness in the LAR distribution before proceeding with the statistical analysis. When examining the associations with the severity of CAP, the LAR was either categorized into tertiles (T) or treated as a continuous variable with 1-unit increments of its ln-transformed values. Multivariable logistic regression models were employed to calculate odds ratios (ORs) along with their corresponding 95% confidence intervals (CIs). To adjust for potential confounding factors, four different models were applied: Model 1 was crude model; Model 2 was adjusted for sex, age; Model 3 incorporated adjustments for all variables included in Model 2, in addition to hypertension, diabetes mellitus, coronary heart disease, chronic lung disease; Model 4 extended the adjustments to include white blood cell, neutrophil, lymphocyte, platelets, c-reactive protein, PCT, PO2/FiO2. Variables were selected for inclusion in the multivariable models mainly based on clinical relevance and previously published literature. To minimize the risk of overfitting given the number of events, we prioritized the inclusion of core confounders and key laboratory parameters known to influence CAP severity. We conducted a subgroup analysis according to sex (Female or Male), age (<80 or ≥80 years), hypertension (YES or NO), diabetes mellitus, coronary heart disease and chronic lung disease to determine if the association between ln-transformed LAR and the severity remained consistent across these various subgroups. A sensitivity analysis was conducted to evaluate whether the main results were influenced by missing data. Participants with incomplete information on covariates were excluded, resulting in a complete-case dataset. The primary association of interest between ln‑transformed LAR and CAP severity was re‑examined using identical multivariable modeling strategies to ensure consistency with the main analysis. ROC curve analysis was used to compare the predictive power of LAR and PSI for the severity of CAP. Data analysis was conducted with R (version 4.2.3) from The R Foundation, as well as Free Statistics software (version 2.1). All statistical tests were two-tailed and significance was assessed at a P-value threshold of less than 0.05. Results Characteristics of the Study This study recruited a total of 423 participants from June 2022- June 2025 (Figure 1). Patients were divided into three tertiles based on LAR: T1 (LAR < 5.02U/g), T2 (5.02 U/g ≤ LAR < 7.85 U/g), and T3 (LAR ≥ 7.85 U/g). Of these participants, 102 (24.1%) were identified with SCAP, while 321 were classified as non-S CAP. The average age of the participants was 73.2±7.5 years. Among them, there were 274 males, accounting for 64.8%. As LAR increased, the proportion of patients with chronic heart failure rose, while the prevalence of chronic lung disease decreased. Laboratory test results showed that ALB levels decreased, while ALT, AST, glucose, Crea, BUN, LDH, PCT, and CRP levels increased. Lymphocyte count, PLT levels and the oxygenation index decreased. The detailed baseline characteristics of all participants are shown in Table 1. Flowchart of our study. Abbreviation: LRTI, lower respiratory tract infection. Table 1Characteristics of The ParticipantsVariablesTotal (n = 423)T1(<5.02, U/g) (n = 141)T2(5.02–7.85, U/g) (n = 140)T3(≥7.85, U/g) (n = 142)pAge, Mean ± SD73.2 ± 7.572.4 ± 7.673.5 ± 7.673.8 ± 7.40.222Sex, Male, n (%)274 (64.8)86 (61)97 (69.3)91 (64.1)0.339Hypertension, n (%)251 (59.5)82 (58.6)85 (60.7)84 (59.2)0.931Diabetes mellitus, n (%)133 (31.4)44 (31.2)41 (29.3)48 (33.8)0.714Coronary heart disease, n (%)87 (20.6)34 (24.1)31 (22.1)22 (15.5)0.171Chronic heart failure, n (%)31 (7.3)4 (2.8)12 (8.6)15 (10.6)0.035Chronic lung disease, n (%)121 (28.6)53 (37.6)45 (32.1)23 (16.2)< 0.001Chronic renal disease, n (%)20 (4.7)3 (2.1)9 (6.4)8 (5.6)0.199PSI, Mean ± SD97.9 ± 31.679.7 ± 20.797.2 ± 29.0116.8 ± 32.4< 0.001ALB, g/L, Mean ± SD34.0 ± 4.937.0 ± 4.433.5 ± 4.331.7 ± 4.4< 0.001ALT, U/L, Median (IQR)18.0 (12.0, 27.0)13.0 (10.0, 19.0)17.5 (12.0, 25.0)23.5 (17.0, 51.8)< 0.001AST, U/L, Median (IQR)24.0 (17.0, 37.0)17.0 (14.0, 21.0)24.0 (18.0, 33.0)44.0 (27.0, 77.5)< 0.001Glucose, mmol/L, Median (IQR)6.9 (5.3, 9.3)6.0 (5.1, 7.9)6.9 (5.4, 8.8)8.3 (5.9, 10.9)< 0.001Crea, umol/L, Median (IQR)72.0 (59.0, 92.5)68.0 (59.0, 83.0)69.0 (56.8, 86.2)82.0 (61.2, 112.0)< 0.001BUN, mmol/L, Median (IQR)6.0 (4.6, 8.7)5.1 (4.4, 6.9)5.7 (4.2, 8.5)7.9 (5.8, 13.1)< 0.001LDH, U/L, Mean ± SD258.6 ± 160.2152.9 ± 26.0206.3 ± 33.3415.0 ± 191.1< 0.001CRP, mg/L, Median (IQR)96.6 (43.2, 188.7)54.6 (16.6, 121.0)99.1 (48.4, 184.2)146.1 (67.1, 209.5)< 0.001PCT, ng/mL, Median (IQR)0.2 (0.1, 1.0)0.1 (0.0, 0.2)0.2 (0.1, 0.7)0.6 (0.2, 2.3)< 0.001WBC, 109/L, Median (IQR)7.7 (5.5, 11.3)7.0 (5.4, 9.3)8.9 (6.2, 12.2)7.6 (5.1, 13.1)0.006NE, 109/L, Median (IQR)6.1 (3.9, 9.7)4.9 (3.6, 7.0)7.4 (4.5, 11.2)6.6 (4.1, 11.9)< 0.001Hb, g/L, Mean ± SD118.8 ± 22.2120.1 ± 21.0118.2 ± 19.5118.2 ± 25.50.725Lymphocyte, 109/L, Median (IQR)0.8 (0.5, 1.3)1.1 (0.8, 1.6)0.9 (0.6, 1.3)0.6 (0.3, 0.8)< 0.001PLT, 109/L, Mean ± SD223.5 ± 107.1249.3 ± 84.9239.6 ± 126.5183.9 ± 93.7< 0.001PH, Mean ± SD7.4 ± 0.17.4 ± 0.17.4 ± 0.17.4 ± 0.10.803PCO2, mmHg, Mean ± SD38.0 ± 11.939.5 ± 10.138.9 ± 14.035.8 ± 10.90.021PO2, mmHg, Mean ± SD90.5 ± 33.594.1 ± 26.789.5 ± 29.188.3 ± 41.80.343PaO2/FiO2, mmHg, Mean ± SD297.5 ± 124.2360.6 ± 98.1308.3 ± 106.9230.8 ± 128.2< 0.001SCAP, n (%)102 (24.1)5 (3.5)19 (13.6)78 (54.9)< 0.001LAR, U/g, Median (IQR)6.0 (4.6, 9.1)4.3 (3.8, 4.6)6.0 (5.5, 6.7)11.3 (9.0, 15.7)< 0.001ln LAR, U/g, Mean ± SD1.9 ± 0.51.4 ± 0.21.8 ± 0.12.5 ± 0.4< 0.001Abbreviations: T, Tertiles; SD, Standard Deviation; IQR, interquartile range; PSI, pneumonia severity index; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood nitrogen urea; LDH, lactate dehydrogenase; PCT, procalcitonin; WBC, white blood cell; NE, neutrophil; Hb, hemoglobin; PLT, platelets; CRP, c-reactive protein; SCAP, severe communicate acquired pneumonia; LAR, lactate dehydrogenase to albumin ratio; ln, natural logarithm. Characteristics of The Participants Abbreviations: T, Tertiles; SD, Standard Deviation; IQR, interquartile range; PSI, pneumonia severity index; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood nitrogen urea; LDH, lactate dehydrogenase; PCT, procalcitonin; WBC, white blood cell; NE, neutrophil; Hb, hemoglobin; PLT, platelets; CRP, c-reactive protein; SCAP, severe communicate acquired pneumonia; LAR, lactate dehydrogenase to albumin ratio; ln, natural logarithm. Association Between LAR and CAP Severity Given the skewed distribution of LAR, we normalized its distribution by applying a ln-transformation. Table 2 presents the relationship of the ln-transformed LAR with CAP severity across four models. Model 1 (Crude model) revealed that ln-transformed LAR was positively linked to CAP severity (OR 23.24, 95% CI 12.09–44.69) when treated as a continuous variable. After adjusting potential confounding variables, Model 4 (Adjusted model) still revealed a positive association between ln-transformed LAR and CAP severity (OR 11.41, 95% CI 3.57–36.47). Meanwhile, categorical analysis using ln-transformed LAR tertiles demonstrated CAP severity associations that were concordant with the continuous variable findings. Participants in the highest tertile (T3) had 8.43 times greater odds of SCAP compared to those in T1 (adjusted OR 9.43, 95% CI 2.22–39.97; see Model 4 in Table 2). Table 2Association Between LAR and Severe Community Acquired PneumoniaModel 1Model 2Model 3Model 4OR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-valueLAR ln transformed23.24 (12.09~44.69)<0.00123.4 (12.12~45.2)<0.00124.12 (12.19~47.71)<0.00111.41 (3.57~36.47)<0.001LAR ln transformed, TertilesT1 (<1.61, U/g)1(Ref)1(Ref)1(Ref)1(Ref)T2 (1.61–2.06, U/g)4.05 (1.47~11.16)0.0073.83 (1.38~10.6)0.013.71 (1.33~10.33)0.0121.3 (0.31~5.4)0.716T3 (≥2.06, U/g)31.68 (12.23~82.06)<0.00131.12 (11.98~80.85)<0.00131.13 (11.79~82.16)<0.0019.43 (2.22~39.97)0.002P for trend<0.001<0.001<0.001<0.001Notes: Model 1:Unadjusted; Model 2:Adjusted for age, sex; Model 3:Adjusted for age, sex, hypertension, diabetes mellitus, coronary heart disease, chronic lung disease; Model 4:Adjusted for age, sex, hypertension, diabetes mellitus, coronary heart disease, chronic lung disease, white blood cell, neutrophil, lymphocyte, platelets, c-reactive protein, PCT, PO2/FiO2.Abbreviations: LAR, lactate dehydrogenase to albumin ratio; T, Tertiles; PCT, procalcitonin; OR, odds ratio. Association Between LAR and Severe Community Acquired Pneumonia Notes: Model 1:Unadjusted; Model 2:Adjusted for age, sex; Model 3:Adjusted for age, sex, hypertension, diabetes mellitus, coronary heart disease, chronic lung disease; Model 4:Adjusted for age, sex, hypertension, diabetes mellitus, coronary heart disease, chronic lung disease, white blood cell, neutrophil, lymphocyte, platelets, c-reactive protein, PCT, PO2/FiO2. Abbreviations: LAR, lactate dehydrogenase to albumin ratio; T, Tertiles; PCT, procalcitonin; OR, odds ratio. Subgroup Analyses The association between ln-transformed LAR and CAP severity remained evident across most subgroups, although a significant interaction was observed with chronic lung disease (P for interaction <0.05), suggesting the effect may vary in specific patient populations (see detailed in Figure 2). Subgroup analyses for the association of LAR and Severe community acquired pneumonia. Adjusted for age, sex, hypertension, diabetes mellitus, coronary heart disease, chronic lung disease, white blood cell, neutrophil, lymphocyte, platelets, c-reactive protein, PCT, PO2/FiO2. Abbreviations: LAR, lactate dehydrogenase to albumin ratio; PCT, procalcitonin. Sensitivity Analysis In the sensitivity analysis of our study, we excluded cases with missing covariate values, ultimately including 350 participants, and the results remained robust. The results continued to indicate that higher LAR levels are associated with greater pneumonia severity(Table 1S). ROC Curve Analysis The comparison of ROC curves for LAR and the PSI score demonstrated equivalent predictive performance regarding CAP severity. The AUC values were 0.853 (95% CI, 0.810–0.896) for LAR and 0.879 (95% CI, 0.845–0.913) for the PSI score, respectively (Figure 3). The optimal cut - off value for LAR was 8.36 U/g, while that for the PSI score was 98 (see Table 3). Comparison of receiver operating characteristic curves between LAR and PSI score for predicting severe community acquired pneumonia. Abbreviations: LAR, lactate dehydrogenase to albumin ratio; PSI, pneumonia severity index. Table 3ROC Analysis of LAR and PSILARPSICut-off8.3698Sensitivity0.760.92Specificity0.830.70Negative predictive value0.920.97Positive predictive value0.600.50Positive likelihood ratio4.473.07Negative likelihood ratio0.290.11Abbreviations: AG, anion gap; SOFA, Sequential Organ Failure Assessment score; ROC Analysis of LAR and PSI Abbreviations: AG, anion gap; SOFA, Sequential Organ Failure Assessment score; Discussion This study provides a focused investigation into the value of the LAR in assessing the severity of CAP in patients over 60 years old. Our core finding is that elevated LAR levels are significantly associated with the severity of CAP. This association remains consistent whether LAR is treated as a continuous variable or a categorical variable, and across different subgroups, highlighting its robustness and potential clinical significance as a novel biomarker. The strong association between elevated LAR and SCAP observed in our study is biologically plausible and aligns with the established roles of its component markers. Prior work has consistently linked higher LDH levels to tissue damage and systemic inflammation across infectious and non-infectious diseases.27–30 while hypoalbuminemia reflects both nutritional deficiency and a heightened acute phase response in older adults with infection.31,32 Our results extend these individual marker associations by demonstrating that their ratio provides incremental value for CAP severity assessment: LDH captures the extent of infection-related tissue injury, while albumin reflects the host’s inflammatory burden and reserve capacity, together encapsulating the balance between insult and physiological compensation in this high-risk population. LAR has garnered increasing attention as an easily detectable biomarker for risk stratification across multiple conditions, combining routine LDH and albumin measures to reflect both tissue damage and systemic inflammation. Our finding that elevated LAR independently predicts SCAP in adults aged 60 years and above aligns with this broader evidence base. Studies have demonstrated that LAR can independently predict poor prognosis in patients with colorectal cancer, breast cancer, esophageal carcinoma, cardiac arrest, and pulmonary embolism,33–37 as well as infectious conditions. For example, elevated LAR has been linked to an increased risk of stroke-associated pneumonia in acute ischemic stroke patients,38 postoperative pneumonia after aneurysmal subarachnoid hemorrhage,39 short-term mortality in acute exacerbation of chronic obstructive pulmonary disease,16 and poor outcomes in lower respiratory tract infection. These consistent findings reinforce the validity of LAR as an inflammatory marker, which is further supported by our results in older adults with CAP. While recent studies by Eksioglu et al and Azapoğlu Kaymak et al have demonstrated the prognostic value of albumin-based composite indices in older adults with CAP,14 the specific predictive role of LAR in this population remains insufficiently explored. Previous research has predominantly focused on the relationship between lower respiratory tract infection prognosis, whereas our study emphasizes the correlation between LAR and the severity of CAP in a specific subgroup of individuals aged 60 and above. Since LDH and albumin are routinely measured in clinical practice, LAR can be easily calculated at admission to help identify high-risk older adults with CAP. Its simplicity and low cost make it a practical tool for early risk assessment, especially in resource-limited settings. Furthermore, ROC curve analysis demonstrated that LAR exhibited a high discriminative ability for predicting SCAP. Although the established PSI score showed slightly better performance, LAR offers a simpler, more readily available, and cost-effective alternative for initial risk stratification, utilizing only two common laboratory parameters. Beyond its statistical association, LAR offers key practical advantages. As LDH and albumin are routine admission tests, LAR requires no extra cost or time to calculate. It can be readily integrated into emergency triage, where an elevated ratio may prompt closer monitoring or earlier intervention. While not a substitute for comprehensive tools like the PSI, LAR provides a complementary metric for early risk stratification, particularly in resource-limited settings. However, this study also has several limitations. First, as a multi-center retrospective study, selection bias is inevitable, and residual confounding cannot be completely ruled out. Regarding data collection, although manual extraction by medical doctors with rigorous double-entry verification enhances data fidelity, it carries inherent risks, including potential human error in coding or data entry and the possibility of missing data for specific variables despite thorough chart review. Second, we only analyzed the LAR level at admission and did not dynamically monitor its changes and their relationship with long - term patient outcomes. Third, our study had a relatively small sample size; future validation in prospective, larger - scale randomized controlled trials is needed. Finally, although LAR was significantly associated with CAP severity, the adjusted odds ratios were accompanied by relatively wide confidence intervals. This indicates substantial uncertainty in the precise estimation of the effect size. Therefore, caution is warranted when interpreting the magnitude of the association, and we avoid overstating the robustness of these findings. Conclusions In conclusion, LAR emerges as a promising and cost-effective predictor of the severity of CAP patients aged ≥60 years, assisting clinicians in identifying high-risk individuals. Although the established PSI score demonstrated slightly better discriminative performance, LAR offers a readily accessible alternative for initial risk stratification using common laboratory parameters. Future studies should further validate the predictive value of LAR in different populations and explore its integration into clinical management pathways to optimize decision-making and improve patient outcomes. Acknowledgments We gratefully thank Dr. Jie Liu of Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital & Physician-Scientist Center of China for his contribution to the statistical support. Funding Statement There is no funding to report. Data Sharing Statement The raw data supporting the findings of this study are available as Supplementary Data, and the sensitivity analysis results are available as Table 1S. Ethics Approval and Informed Consent This study was approved by the Ethics Committee of Beijing Luhe Hospital, Capital Medical University (No: 2022-LHKY-040-03). The requirement for obtaining written informed consent from participants was waived by the Ethics Committee due to the retrospective nature of the study and the use of anonymized data. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure All authors report no conflicts of interest in this work. References Associated Data Data Availability Statement The raw data supporting the findings of this study are available as Supplementary Data, and the sensitivity analysis results are available as Table 1S.